Delayed tacrolimus is safe with basiliximab induction therapy

Liver Transplantation

Volumn 8, Issue 8, 2002, Pages 732-

  Lee, Kang H ^a   Da Costa, Maureen ^a   Lim, Seng Gee ^a   Tan, Kai Chah ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; BASILIXIMAB; HYBRID PROTEIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

CADAVER DONOR; CONTROLLED STUDY; DRUG SAFETY; GRAFT REJECTION; HEPATITIS C; HUMAN; KIDNEY FAILURE; LETTER; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT FAILURE; ADULT; CADAVER; DONOR; DRUG ADMINISTRATION; METHODOLOGY; NOTE; POSTOPERATIVE PERIOD; SAFETY;

ADULT; ANTIBODIES, MONOCLONAL; CADAVER; DRUG ADMINISTRATION SCHEDULE; HUMAN; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; METHYLPREDNISOLONE; POSTOPERATIVE PERIOD; SAFETY; TACROLIMUS; TISSUE DONORS; HUMANS; RECOMBINANT FUSION PROTEINS;

EID: 0036342052     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2002.34679     Document Type: Letter

References (4)

1. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients
2. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: Results froma double-blind randomized placebo-controlled trial
3. Pros and cons of using interleukin-2 receptor antibodies in liver transplant recipients
4. Experience with daclizumab in liver transplantation: Renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation